Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Dose Escalation / Dose Expansion Study of NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

Next Previous
X
Search
Trial Profile

A Phase I Dose Escalation / Dose Expansion Study of NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hafnium oxide (Primary) ; Nivolumab; Pembrolizumab
  • Indications Bladder cancer; Cancer metastases; Cervical cancer; Gastric cancer; Head and neck cancer; Liver cancer; Liver metastases; Lung cancer; Malignant melanoma; Merkel cell carcinoma; Non-small cell lung cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
  • Focus Adverse reactions; First in man
  • Sponsors Nanobiotix

    • Most Recent Events

    • 12 Jun 2024 According to a Nanobiotix media release, company will host a virtual KOL (Key Opinion Leader) event Tuesday June 18, 2024 at 9:00-10:30AM EDT / 3:00-4:30PM CEST to discuss the Role of NBTXR3 and Immune Oncology in Advancing Head & Neck Cancer.
    • 04 Jun 2024 Results assessing early signs of efficacy in patients with anti-PD-1 naive and anti-PD-1 resistant HNSCC treated with NBTXR3/SBRT in combination with nivolumab or pembrolizumab were presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 02 Jun 2024 According to a Nanobiotix media release, data from this trial were presented at the 2024 Annual Meeting of the American Society for Clinical Oncology (ASCO 2024).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top